Kornimate/medical-research-clean huggingface dataset:
early intensive physical therapy in subarachnoid hemorrhage

Conditions: Subarachnoid Hemorrhage

Summary: this study will investigate the safety and feasibility of early intensive physical therapy for patients diagnosed with subarachnoid hemorrhage. intervention will begin in the neurological intensive care unit (icu) and continue for 30 days or hospital discharge.


Eligibility criteria:
inclusion criteria: * patients diagnosed by ct scan or mri with subarachnoid hemorrhage and admitted to the neurological icu \>48 hours. exclusion criteria: * significant language barrier that would limit the ability to participate in the physical therapy program * severe baseline physical or cognitive impairment that would impair their ability to participate in the protocol * patients whose vital signs are outside the accepted starting and stopping criteria outlined below: 1. intracranial pressure ≤ 15 mm hg 2. cerebral perfusion pressure \>50 or \<70 mm hg 3. mean arterial pressure ≥ 80 and ≤ 110 4. heart rate ≥40 and \<140 bpm 5. pulse oximetry \>88%

Keywords: physical therapy, early intervention
community-acquired methicillin-resistant staphylococcus aureus carriage among athletes

Conditions: Staphylococcus Aureus

Summary: there are only very few data about the prevalence of ca-mrsa in france and no in athletes. in usa, the clone usa300 is widely disseminated and in europe the clone st80 predominates. the aim of the study was to study the carriage of s. aureus in athletes in a french county (limousin) and to evaluate the proportion of ca-mrsa. the athletes will be met during their training, each one will fill-in a clinical information questionnaire. nasal, throat, inguinal and skin lesions swab samples will be performed. the antibiotic susceptibility profile of the staphyloccocus aureus strains isolated will be performed as well as the detection of the pvl gene. strains will also be typed by different molecular methods (pgfe (pulsed gel field electrophoresis), sccmec type (staphylococcal chromosome cassette mec), and mlst (multilocus sequence typing)). the cic (clinical investigation center) of the limoges university hospital will be in charge of the inclusions of the athletes. the sample analysis will be centralized and performed at the laboratory of bacteriology of the limoges university hospital. a clinical research officer of the limoges university hospital will be in charge of the survey of the study and will organize monthly meetings with all the participants of the study.


Eligibility criteria:
inclusion criteria: * adult patients (over 18), * belonging to a sport club of limousin, practicing rugby, wrestling, basket-ball, volley-ball, hand-ball, fence, martial art, football, weight lifting, and base-ball. * patient having signed in a free way and lit his consent to participate in this study exclusion criteria: * clinical information questionnaire not possible to fill, * swab sample not possible to realize.

Keywords: - staphylococcus aureus carriage among athletes
the effect of transcranial direct current stimulation of the primary motor and somatosensory cortex on pain thresholds.

Conditions: Healthy

Summary: the purpose of this study is to investigate the modulatory effect of a novel tdcs configuration on the pain sensitivity in healthy subjects.

the purpose of this study is to investigate the modulatory effect of a single session 20 min anodal primary motor cortex (m1) and cathodal primary somatosensory cortex (s1) transcranial direct current stimulation (tdcs) on the pain sensitivity on the descending part of musculus trapezius in healthy young adults.

Eligibility criteria:
inclusion criteria: * healthy * age between 18-30 years * living in denmark exclusion criteria: * pregnancy * drug addiction defined as the use of cannabis, opioids or other drugs * current use of opioids, antipsychotics, benzodiazepines * previous or current neurological, musculoskeletal, rheumatic, malignant, inflammatory or mental illnesses * current or prior chronic pain conditions * lack of ability to cooperate
endomet - novel diagnostic tools and treatments for endometriosis

Conditions: Endometriosis

Summary: endometriosis is a chronic disease characterized by the presence of functional endometrial glands and stroma in ectopic locations outside the uterine cavity. the ectopic endometrial tissue responds to estradiol and other hormones similarly to the normal endometrium. endometriosis is one of the most common benign gynecological conditions, as many as 5-10% of women in the reproductive age may be affected. in addition to pain which may be severe, subfertility is one of the typical problems associated with endometriosis and may be present in up to 40% of those affected. there is lack of a clear correlation between severity of pain and degree of compromised fertility. different modes of treatment exist. hormonal treatments are based on the suppression of estrogenic action on endometriosis as well as the endometrium. unfortunately, discontinuation of the hormonal treatment typically results in a rapid recurrence of the disease. surgery may alleviate the symptom for different lengths of time, however, curative treatment frequently involves hysterectomy with bilateral oophorectomy. in order to escape this radical treatment, new targeted therapy in the form of novel pharmacological agents would be of crucial importance. presently, endometriosis can be reliably diagnosed only by laparoscopy. since this is an invasive surgical procedure, new diagnostic tools would be warmly welcomed. furthermore, as the progression of the disease is presently impossible to predict, new markers for the "malignancy" of each case are desperately needed. the aim of the investigators research is to identify expression of endometriosis specific rnas/proteins. evaluation of expression profiles in samples of endometriosis and endometrium of patients with careful clinical and surgical classification of endometriosis as well as healthy control women should initially enable to identify novel targets for new therapies and biomarkers. particularly the different pain symptoms will be recorded annually and evaluated comprehensively. furthermore, combined with an adequate 10-year follow up (based on a questionnaire, including fertility, received treatments and different pain symptoms; nrs), the study should enable for example to identify markers for endometriosis associated infertility as well as cases where the disease progresses very rapidly or reoccurs. different forms of effective treatment may thereafter be designed following the identification of such factors.


Eligibility criteria:
inclusion criteria: * study group: surgically and pathologically verified endometriosis * control group: existence of endometriosis ruled out in laparoscopy exclusion criteria: * no other significant disease or medication for other diseases * suspicion of malignancy * pregnancy * acute infection * insufficient understanding of finnish language * previous hysterectomy and/or bilateral salpingo-oophorectomy

Keywords: endometriosis dysmenorrhea infertility biomarker drug target recurrence complications dyspareunia dyschezia dysuria chronic pelvic pain surgical treatment long-term follow-up
bone marrow transplantation in treating children with sickle cell disease

Conditions: Sickle Cell Anemia

Summary: rationale: sickle cell disease is an inherited disorder in which abnormal, crescent-shaped red blood cells interfere with the ability of the blood to carry oxygen through the body and can cause severe pain, stroke, and organ damage. bone marrow transplantation, is a procedure in which the soft, sponge-like tissue in the center of bones producing white blood cells, red blood cells, and platelets is replaced by bone marrow from a another person. bone marrow transplantation may be an effective treatment in relieving the symptoms of sickle cell disease. purpose: phase i/ii trial to study the effectiveness of bone marrow transplantation in treating children who have sickle cell disease.

protocol outline: this is a multicenter study. patients undergo total body irradiation on day 0, followed by allogeneic bone marrow transfusion. patients also receive fludarabine iv daily and cyclosporine iv twice a day on days -1 to 1. patients then receive oral cyclosporine on days 1-90, and oral mycophenolate mofetil twice a day on days 0-27. patients are followed for 100 days, monthly for 6 months and then annually for 2 years.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- diagnosis of sickle cell anemia with clinically severe disease manifestations defined by: recurrent painful events (at least 2 painful events in past year) which cannot be explained by other causes pain lasts at least 4 hours requires treatment with parenteral narcotics, equianalgesic dose of oral narcotics, or parenteral nonsteroidal antiinflammatory drugs acute chest syndrome (acs) with at least 2 episodes within past 2 years that required hospitalization, oxygen, and rbc transfusion any combination of painful events and acs episodes that total 2 events within the past year abnormal cerebral mri, abnormal angiography (mr or conventional), and abnormal neuropsychologic testing performance no stage iii or iv sickle cell lung disease genotypically hla identical sibling donor available --prior/concurrent therapy-- no prior transfusions with greater than 5 units rbc --patient characteristics-- performance status: karnofsky 70-100% hepatic: * no active hepatitis * no moderate/severe portal fibrosis renal: glomerular filtration rate at least 30% predicted for age neurologic: * no severe residual functional neurologic impairment * hemiplegia alone allowed other: * hiv negative * not pregnant or nursing * fertile patients must use effective contraception

Keywords: genetic diseases and dysmorphic syndromes hematologic disorders rare disease sickle cell anemia
sacral neuromodulation in children and adolescents

Conditions: Chronic Constipation With Overflow; Encopresis With Constipation and Overflow Incontinence; Hirschsprung's Disease; Anorectal Malformations; Sacral Dysgenesis

Summary: the purpose of this study is to assess the efficacy of neuromodulation for treatment of chronic constipation and fecal incontinence in pediatric patients and to evaluate the differences between the invasive vs. non-invasive approach.

patients are selected according to the eligibility requirements. after obtaining informed consent off-label use and potential risks of sacral neuromodulation, all included patients and next of kin give written informed consent to the study. at baseline, patients are randomized to one of the two predefined subgroups: either invasive sacral neuromodulation or non-invasive sacral neuromodulation. clinical symptoms and outcome variables are compared regarding the beginning of non-invasive sacral neuromodulation or the implantation of the tined lead electrode. patients are closely monitored within 6 months. treatment success is evaluated in routine clinical check-ups (week 4/8/12 and 24) and via specialized questionnaires and bowel movement diaries. quality of life is evaluated at baseline and after 12 and 24 weeks of treatment.

Eligibility criteria:
inclusion criteria: * age between 2-17 years * informed consent * chronic constipation according to the rome iv criteria for more than 3 months with or without encopresis/soiling despite underlying diseases such as slow-transit constipation, rectal evacuation disorders or hirschsprung's disease. * refractory to conventional treatment in an appropriate weight-adapted application (training for bowel movements, lifestyle changes, pelvic floor training, pharmacological options) * in cases of hirschsprung's disease: diagnosis confirmed histologically by rectal biopsies and in case of resection of an aganglionic segement: period between surgery and snm at least 1 year * in cases of anorectal malformation or mechanical obstruction: post-surgical status: period between surgery and snm at least 1 year exclusion criteria: * metabolic, inflammatory, and hormonal causes for chronic constipation * toxic megacolon or further emergencies, which must be treated surgically * sacral fractures or substantial differences in the sacral anatomy * inflammatory bowel disorders * rectal prolapse * neuronal malignancies under medical and radiation therapy * seizures

Keywords: sacral nerv stimulation neuromodulation
effect of dual task exercise on cognitive and physical function in the elderly with mild cognitive impairment

Conditions: Cognitive Dysfunction; Mild Cognitive Impairment

Summary: the purpose of this study is to investigate the effect of the dual task exercise program on cognitive and physical function in the elderly with mild cognitive impairment.

all participants provided written informed consent before study participation. a total of 12 community-dwelling participants were randomized either to the exercise group or to the control group. the exercise group underwent 8-week, 3 times a week, 60-minute group exercise sessions, which were comprised of moderate-to-high intensity exercise and simultaneous cognitive tasks. they also performed moderate-intensity home aerobic exercises for at least 60 minutes per week. the control group performed 60-minute light intensity home exercise, 4 times a week for 8 weeks.

Eligibility criteria:
inclusion criteria: * a score on the korean montreal cognitive assessment (moca-k) of 25 points or below * aged 65 or more * no physical or medical problem which impairs moderate to vigorous physical activity exclusion criteria: * uncontrolled or unstable cardiovascular disease * malignancy affecting general condition * musculoskeletal problems affecting motor performance * speech and hearing impairment * other organic brain diseases
a study to estimate effect of 4 different doses of azd3355 on reflux episodes, which patients with gastroesophageal reflux disease (gerd) may experience

Conditions: Gastroesophageal Reflux Disease

Summary: the purpose of the study is to estimate what effect 4 different doses of azd3355 will have on the number of reflux episodes, in patients who have gerd and still experience symptoms despite proton pump inhibitor (ppi) treatment.


Eligibility criteria:
inclusion criteria: * provide informed consent * history of gerd with persistent symptoms despite treatment with ppi * otherwise normal physical health exclusion criteria: * history of gerd with symptoms that has not improved at all during treatment with ppi * prior surgery of the upper gastrointestinal tract * history of significant heart disease, cardiovascular, respiratory, hepatic, renal, metabolic, psychiatric or gastrointestinal disorders besides gerd

Keywords: gerd lesogaberan impedance ph pharmacokinetics safety tolerability
dietetic intervention with soluble fiber in type 2 diabetes mellitus (dm) patients with metabolic syndrome (ms)

Conditions: Metabolic Syndrome; Albuminuria

Summary: metabolic syndrome (ms) is an clinical condition with high cardiovascular risk. more than 80% of dm patients had ms. dietary factors can be associated to both, dm and ms. therefore the aim of this study is to evaluate the effects of add soluble fiber (goma-guar) in the usual diet of type 2 dm with ms and compare this intervention with an usual diet without this supplement.

the aim of this study was to evaluate the effect of soluble fiber (guar gum) on the ms components (international diabetes federation-2005 and who): blood pressure, plasma glucose, triglycerides, hdl, central obesity (waist, bmi),and albuminuria. secondary objectives are: effect of guar gum on serum fatty acids, , pcr, endothelin 1, and fibrinogen. primary outcomes were alterations on ms components. forty-four type 2 diabetic outpatients were included in a randomized clinical trial: treatment 1- guar gum (10g/day) + usual diet; treatment 2- usual diet. the duration of each treatment was six weeks. three days weight diet records with concurrent 24h urinary collections (protein intake estimative), clinical and laboratory evaluation were performed at baseline and after 4 and 6 weeks. serum fatty acids were measured in total triglycerides fractions by gas chromatography.

Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes * using metformin and/or insulin exclusion criteria: * serum triglycerides \> 400 mg/dl * serum creatinine \> 2 mg/dl * gastrointestinal malabsorption

Keywords: metabolic syndrome diet fiber serum lipids albuminuria
efficacy of two intermittent subglottic secretion

Conditions: Ventilator Associated Pneumonia

Summary: the purpose of this study is to determine the efficacy of intermittent subglottic secretion lavage combined with aspiration preventing ventilator associated pneumonia in patients with severe neurological disease

ventilator-associated pneumonia (vap) is a common and serious complication of mechanical ventilation. many studies have shown that the accumulation of subglottic secretions above the endotracheal cuff plays an important role in the pathogenesis of vap. subglottic secretion drainage (ssd) has been shown to be associated with a lower incidence of vap in previous meta-analyses. most studies in past reported that in the group of patients in whom endotracheal tube (ett) was used and subglottic secretion drainage was applied compared to the group without subglottic secretion drainage.very few studies compared two different methods of ssd,such as subglottic secretion lavage combined with aspiration or pure aspiration.the tubes need frequent cleaning as they often get blocked, especially the draining duct. this may be the reason why they are not commonly applied. however,subglottic secretion lavage combined with aspiration can reduce the incidence of tube blockage.so the purpose of this study is to determine the efficacy of intermittent subglottic secretion lavage combined with aspiration preventing ventilator associated pneumonia in patients with severe neurological disease.

Eligibility criteria:
inclusion criteria: * patients aged between 18 and 80 years requiring mechanical ventilation for more than 72 hours with placement of an ett( equipped with a dorsal suction catheter for subglottic secretion drainage) exclusion criteria: * exclusion criteria were patients endotracheal intubation was performed before admission, history of hiv, immunosuppression, leukopenia, patient refusal,and

Keywords: ventilator-associated pneumonia subglottic secretion drainage endotracheal tube length of mechanical ventilation
is robot-assisted therapy effective for the upper extremity following a stroke

Conditions: Stroke

Summary: the aim of this study was to investigate the effects on upper-limb motor function of the addition of robotic rehabilitation (rr) and conventional rehabilitation (cr) treatments to intensive trunk rehabilitation (itr). a total of 41 subacute stroke patients were randomly allocated to two groups: rr and cr. both groups received the same itr procedure (6x5x60 weeks/days/minutes). following itr, a robot-assisted rehabilitation program of 60 minutes, five days a week, for six weeks, was applied to the rr group, and an individualized upper extremity rehabilitation program to the cr group. evaluations were made at baseline and after six weeks using the trunk impairment scale (tis), fugl-meyer upper extremity motor evaluation scale (fma-ue), and wolf motor function test (wmft).

assessments: - demographic data form: the researchers created a form to include the information on age, gender, stroke onset date, lesion type, affected side, and dominant extremity. - fugl-meyer upper extremity assessment: this disease-specific scale was created as an objective motor impairment scale to assess recovery in post-stroke hemiplegic patients (18). it includes subsections that assess joint movements, coordination, and reflex activities related to the shoulder, elbow, forearm, wrist, and hand. the maximum score that can be obtained is 66, with a high score indicating good motor condition. the affected upper extremities are assessed with the subject in a seated position. - wolf motor function test: this test was created to evaluate the motor ability of the upper extremity (19). the test consists of 17 items, 15 of which are related to the fields of functional skill and performance time, and 2 to muscle strength (20). the total score is used for the functional ability of the patients. the two items of muscle strength evaluation were not used in this study. - trunk impairment scale: this scale evaluates static and dynamic sitting balance and trunk coordination with seventeen items. the total score ranges from 0 - 23 points, with a higher score indicating better performance. the test-retest and inter-rater reliability coefficients of the scale have been shown to be 0.85-0.99 (21).

Eligibility criteria:
inclusion criteria: * age 40-85 years and having had a stroke in the last six months, * mini-mental state assessment score \>20, * able to sit safely, * no neglect issue, * fugl-meyer upper extremity assessment score \<58. exclusion criteria: * modified ashworth scale \>2, * severe reduction in visual acuity, * participation in another rehabilitation program, * subluxation or pain in the shoulder region.

Keywords: robotic rehabilitation conventional rehabilitation intensıve trunk rehabilitation motor function
phase 3 study to evaluate the efficacy and safety of lib003 with evolocumab in hofh

Conditions: Homozygous Familial Hypercholesterolemia

Summary: to compare the safety, tolerability and ldl-c response after 24 weeks of monthly (every 4 weeks \[q4w\]) subcutaneous (sc) dosing of lib003 300 mg with monthly (q4w) sc dosing of 420 mg evolocumab (repatha®) in patients with hofh on stable diet and oral ldl-c-lowering drug therapy

patients with verified hofh on stable and continuing doses of oral lipid lowering therapy will be randomized to either evolocumab 420 mg q4w or lib003 300 mg q4w for 24 weeks (period a). at week 24, subjects will be crossed over to lib003 if they were on evolocumab and vice versa for the next 24 weeks (period b).

Eligibility criteria:
inclusion criteria: * hofh diagnosed clinically and confirmed by genotyping * weight of \>30 kg and body mass index (bmi) \>17 and \<40 kg/m2 * stable diet and lipid-lowering oral therapies for at least 4 weeks exclusion criteria: * mipomersen within 6 months of screening; * ldl or plasma apheresis \<2 months prior to randomization * history of non-response to pcsk9 mab or presence of receptor negative/null ldlr activity expected to result in non-response to pcsk9 inhibition * prior or active clinical condition or acute and/or unstable systemic disease compromising subject inclusion

Keywords: ldl cholesterol pcsk9 inhibition